Has a known history of HIV (HIV 1/2 antibodies), active / chronic Hepatitis B or C.
Known infection with HIV, hepatitis B, or hepatitis C
Known active or chronic hepatitis B or C infection or HIV
Patients who have HIV, Hepatitis B or C
Active hepatitis B or C or a history of HIV infection
Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to Hepatitis B or C without evidence of active infection may be allowed.
Known history of HIV, hepatitis C or hepatitis B infection
Known history of HIV, hepatitis B, or hepatitis C infection
History of Hepatitis B, C, or HIV
Known to be positive for HIV or hepatitis B, or known to have active hepatitis C infection
Known active hepatitis B or C or known infection with HIV
Known history of active tuberculosis (TB), autoimmune disease, pneumonitis, infection, HIV, Hepatitis B, or Hepatitis C
Known history of active tuberculosis (TB), autoimmune disease, pneumonitis, infection, HIV, Hepatitis B, or Hepatitis C
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive; patients who have previously tested positive for hepatitis B core antibody may be eligible if they are confirmed to NOT have active disease and are on appropriate anti-viral therapy; no additional hepatitis or HIV testing is required for patients who have been evaluated during their induction and/or pre-transplant work-up and have had no clinical evidence of HIV, hepatitis B or hepatitis C since their last evaluation
Patients with known active Hepatitis C, HIV or a present history of Hepatitis B
Hepatitis B or HIV infection
Evidence of active Hepatitis B, active Hepatitis C infection (HCV) or cytomegalovirus (CMV) or known history of HIV.
Known history of HIV or active hepatitis B/C (patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible)
No active hepatitis or diagnosis of HIV disease.
Known to be positive for HIV, Hepatitis B, or Hepatitis C
Known HIV, Hepatitis A, B or C infection.
Known active infection with HIV, hepatitis B, hepatitis C
Patients known to be HIV positive or have active viral hepatitis.
Patients must have a negative test for HIV, Hepatitis A, B, and C.
Known HIV-positive or Hepatitis C
Active HIV or hepatitis B or C infection
Known history of HIV disease, active hepatitis B or hepatitis C.
Known history of Hepatitis B or C or HIV
Has uncontrolled HIV or hepatitis B or C
Patients currently known to be positive for, HIV, hepatitis B or C.
Patient with known active infection with HIV, hepatitis B or hepatitis C
Known HIV positive or active hepatitis B or C
Patients with a known confirmed diagnosis of HIV infection or active viral hepatitis.
Patients with known active hepatitis B or C, or HIV infection.
Known HIV, Hepatitis B, or Hepatitis C.
Patients who are known to be HIV or hepatitis C positive.
Patients with known HIV, hepatitis B or C;
Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to Hepatitis B or C without evidence of active infection may be allowed.
Patients who have a known history of hepatitis C or chronic active hepatitis B or a known diagnosis of HIV
Active HIV, hepatitis B or C
Patients must not have a history of HIV, or active Hepatitis A, B, and C.
Known HIV or chronic Hepatitis B or C infection.
Known active or chronic hepatitis B or C infection or HIV
Known HIV-, hepatitis B-, or hepatitis C-positive patients (active, previously treated, or both)
Known HIV, active hepatitis B or active hepatitis C infection
Subject with known active HIV, Hepatitis B, or Hepatitis C infections.
Known to be positive for HIV or known to have active hepatitis B or C.
HIV/active Hepatitis B or C infection
Patients must not have known HIV, hepatitis B or hepatitis C positivity
Known history or evidence of active hepatitis A, B, or C or HIV
Known positive HIV infection, or active hepatitis B or C infection
Known history of HIV infection or a known history of or is positive for Hepatitis B or Hepatitis C
Concurrent severe and/or uncontrolled medical conditions (uncontrolled diabetes or infection), known infection with HIV, Hepatitis B or Hepatitis C.
Patients with known active hepatitis or HIV.
Known systemic infections including, but not limited to hepatitis B or C, or HIV
Current infection with HIV, Hepatitis B or Hepatitis C. Patients will have serologic testing performed during screening for HIV and Hepatitis B and C. Any serologic results suggestive of an ongoing viral infection will be further investigated as necessary to clarify the patient's status.
Known HIV or hepatitis B or C viral infection
Known infection with hepatitis B, hepatitis C, or HIV.
Known infection with hepatitis B, C or HIV
Known HIV or active hepatitis B or C infection
Patients who have HIV, Hepatitis B or C
Known immunodeficiency or HIV, Hepatitis B or Hepatitis C positivity.
Evidence of active Hepatitis B or C or HIV
Known history of HIV or hepatitis C or B
HIV positive or active Hepatitis A or B
Clinical or laboratory evidence of active hepatitis B or hepatitis C 8. History of HIV infection.
Infection with HIV or hepatitis B or C at screening
Patient has known historical or active infection with HIV, hepatitis B, or hepatitis C
Active hepatitis and/or known HIV carrier
Patients who are known to be HIV positive and/or have active hepatitis B or C infection
No patients known to be positive for HIV, or active Hepatitis A, B, or C.
Known HIV or hepatitis A, B, or C positivity---ONLY IF ACTIVE
Known HIV and/or Hepatitis B or C infections
Positive for Hepatitis B, Hepatitis C, or HIV
Known HIV or active hepatitis B or C viral infection.
Current infection with HIV, Hepatitis B or Hepatitis C
Known infection with HIV, HTLV-I, Hepatitis B, or Hepatitis C.
Known HIV, hepatitis B or hepatitis C.
History of or current active infection with hepatitis B, hepatitis C or HIV
Known chronic active Hepatitis B or C, or HIV infection
Past medical history of infection with HIV, hepatitis B or hepatitis C
Known to be positive for HIV, or to have active hepatitis B, or hepatitis C, or have active infection of any kind requiring systemic therapy
Current known active infection with HIV, hepatitis B or C viruses
Infection with HIV or hepatitis B or C at screening
Known HIV, Hepatitis A, B or Hepatitis C infection
Known history of Hepatitis B or C infection or HIV infection
Known active Hepatitis B/ Hepatitis C/ HIV infection
History of HIV, hepatitis B, or hepatitis C
Known HIV positive or Hepatitis A, B, or C infection
Infection with HIV or hepatitis B or C at screening
Patient has known or suspected HIV, positive for hepatitis B or is known or suspected to have active hepatitis C infection.
Active infection including HIV, hepatitis A, B or C
known HIV or Hepatitis
Known history of HIV or active hepatitis B/C (patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible)
Known history of HIV or active hepatitis B/C )
FOR THE 31 SUBJECTS ENROLLED IN YEAR 1: History of known active infection with HIV, hepatitis B or hepatitis C
Patients with a known confirmed diagnosis of HIV infection or active viral hepatitis.
Known HIV or active hepatitis B or C infection
Current infection with HIV, Hepatitis B or Hepatitis C
Known history of HIV or Hepatitis C
Known active or chronic hepatitis B or C infection or HIV
Known HIV or active hepatitis B or C viral infection
Active cytomegalovirus (CMV) retinitis, or other active CMV-related organ dysfunction
EXCLUSION - PROCUREMENT: Clinically significant viral infection or uncontrolled viral reactivation of Epstein Barr virus (EBV), cytomegalovirus (CMV), adenovirus (Adv), BK-virus, or human herpesvirus 6 (HHV-6)
Active viral infection requiring treatment with anti-viral medication (uncomplicated cytomegalovirus [CMV] viremia that is responding to antiviral medications is allowed)
Active or recent herpes simplex virus (HSV) infection or cytomegalovirus (CMV) based on symptoms with positive swab culture and/or positive Immunoglobulin M (IgM) screening, which would complicate the post-conditioning period
Active or recent herpes simplex virus (HSV) infection or cytomegalovirus (CMV) based on symptoms with positive swab culture and/or positive IgM screening
Patients with history of (h/o) pneumocystis pneumonia (PCP) or positive cytomegalovirus (CMV) viremia confirmed twice at least 1 day apart at screening
At time of protocol enrollment, the patient should be negative for cytomegalovirus (CMV) by antibody testing or by PCR; in case of disagreement between these 2 CMV tests, the tests will be repeated and department (Dept.) of Laboratory Medicine consulted
Cytomegalovirus (CMV) infection. Patients who are CMV PCR positive at baseline will not be eligible.
Any history or evidence of opportunistic infection within 6 months of screening including tuberculosis, severe cytomegalovirus (CMV) or herpetic infections (such as disseminated herpes, herpes encephalitis, ophthalmic herpes)
Cytomegalovirus (CMV) infection. Patients who are CMV PCR positive at baseline will not be eligible
DONOR: Any cord blood units without the full maternal testing and negative results for hepatitis A, B, C, HIV, and human T-lymphotropic virus (HTLV-1) viruses; any additional available virology results on the unit itself will be reviewed but are not mandated, complete or always available; cord blood units are presumed to be cytomegalovirus (CMV) negative regardless of serologic testing due to passive transmission of maternal CMV antibodies
Active acute infection, except for Herpes viruses (cytomegalovirus [CMV], Epstein Barr virus [EBV], herpes zoster virus [HZV], herpes simplex virus 1 [HSV 1]).
Evidence of end-organ Cytomegalovirus (CMV) infection
Cytomegalovirus (CMV)- Ongoing infection, treatment, or prophylaxis within the past 28 days
Cytomegalovirus colitis or enteritis as defined by cytomegalovirus (CMV) shell vial or culture positivity from endoscopic biopsy the discretion of the treating physician based upon PCR positivity, clinical presentation and histology
Active cytomegalovirus (CMV) retinitis or other active CMV-related organ dysfunction; patients with a history of treated CMV infection are not excluded
Active cytomegalovirus (CMV) retinitis or other active CMV-related organ dysfunction; patients with a history of treated CMV infection are not excluded
Evidence of severe retinopathy (e.g. cytomegalovirus [CMV] retinitis, macular degeneration) or clinically relevant ophthalmological disorder (e.g. due to diabetes mellitus or hypertension)
Evidence of severe retinopathy (e.g. cytomegalovirus [CMV] retinitis, macular degeneration) or clinically relevant ophthalmological disorder (e.g. due to diabetes mellitus or hypertension)
Positive cytomegalovirus (CMV) PCR test at baseline
Active Cytomegalovirus (CMV) retinitis or other CMV-related organ dysfunction.
MATCHED RELATED DONOR: Presence of any blood transmissible infectious disease that cannot be cleared prior to stem cell collection and poses an unacceptable risk for the recipient (excludes cytomegalovirus [CMV])
No uncontrolled bacterial, fungal or viral disease (therapy for cytomegalovirus [CMV] viremia is permitted)
Cytomegalovirus (CMV) PCR positive at baseline
Infections\r\n* ARM A: Without active uncontrolled bacterial, fungal or viral infection\r\n** Cytomegalovirus (CMV)- If CMV viremia is < 137 IU/ml, but patients are on therapy for CMV\r\n** Human herpes virus (HHV)-6 < 40,000 copies/ML and without active trend up\r\n* ARM B: No limitation
Active cytomegalovirus (CMV) disease at the time of enrollment
Persistent or recurrent cytomegalovirus infection or disease despite at least 7 days of standard therapy or failure of therapy as described below or if unable to tolerate standard therapy. Standard therapy is defined as antiviral therapy with ganciclovir or CMX001 (brincidofovir) as the agents of choice and foscarnet or cidofovir as second line agents. i.Cytomegalovirus infection: defined as the presence of CMV positivity as detected by Polymerase chain reaction (PCR) or pp65 antigenemia or culture from ONE site such as stool or blood or urine or nasopharynx. ii. Cytomegalovirus disease: defined as the demonstration of CMV by biopsy specimen from visceral sites (by culture or histology) or the detection of CMV by culture or direct fluorescent antibody stain in broncheoalveolar lavage fluid in the presence of new or changing pulmonary infiltrates or changes consistent with CMV retinitis on ophthalmologic examination. iii. Failure of therapy: defined as a rise or a fall of less than 50% in viral load in peripheral blood or any site of disease as measured by PCR or pp65 antigenemia after 7 days of antiviral therapy.
Active infection including cytomegalovirus
Cytomegalovirus (CMV): Ongoing infection, treatment, or prophylaxis within the past 28 days
Patients will be eligible following any type of allogeneic transplant if they have CMV, adenovirus or EBV infection persistent to standard therapy (as defined below):\r\n* Prior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant using either bone marrow, peripheral blood stem cells or single or double umbilical cord blood\r\n* CMV, adenovirus or EBV infection persistent despite standard therapy\r\n** For CMV infection:\r\n*** Patients with CMV disease defined as the demonstration of CMV by biopsy specimen from visceral sites (by culture or histology) or the detection of CMV by culture or direct fluorescent antibody stain in bronchoalveolar lavage fluid in the presence of new or changing pulmonary infiltrates OR\r\n*** Failure of antiviral therapy defined as the continued presence of pp65 antigenemia (> 1+ cell/100,000 cells) or deoxyribonucleic acid (DNA)emia (as defined by reference lab performing polymerase chain reaction [PCR] assay but usually > 400 copies/ml) after at least 7 days of antiviral therapy OR\r\n*** Relapse after antiviral therapy defined as recurrence of either pp65 antigenemia or DNAemia after at least 2 weeks of antiviral therapy\r\n** For CMV infection, standard therapy is defined as 7 days therapy with ganciclovir, foscarnet or cidofovir for patients with disease or recurrence after 14 days therapy\r\n** For EBV infection:\r\n*** EBV infection is defined as biopsy proven lymphoma with EBV genomes detected in tumor cells by immunocytochemistry or in situ PCR OR clinical or imaging findings consistent with EBV lymphoma and elevated EBV viral load in peripheral blood\r\n*** For EBV infection, standard therapy is defined as rituximab given at 375 mg/m^2 in patients for 1-4 doses with a CD20 positive (+) tumor\r\n*** Failure is defined as there was an increase of less than 50% response at sites of disease for EBV lymphoma OR there was a rise or a fall of less than 50% in EBV viral load in peripheral blood or any site of disease\r\n** For adenovirus infection or disease:\r\n*** Adenovirus infection is defined as the presence of adenoviral positivity as detected by PCR, DAA or culture from ONE site such as stool or blood or urine or nasopharynx OR adenovirus disease will be defined as the presence of adenoviral positivity as detected by culture from two or more sites such as stool or blood or urine or nasopharynx\r\n*** Standard therapy is defined as 7 days therapy with cidofovir (if renal function permits this agent to be given)\r\n*** Failure is defined as a rise or a fall of less than 50% in viral load in peripheral blood or any site of disease as measured by PCR or any other quantitative assay
Cytomegalovirus (CMV) viremia.
Active infection with cytomegalovirus (CMV) as defined as CMV viral load >= 10,000 copies per mL of whole blood; CMV viral load testing is only required if the patient has clinical signs or symptoms suggestive of active CMV infection
Known uncontrolled cytomegalovirus (CMV) polymerase chain reaction (PCR) reactivation per institutional standards; once CMV has been treated and stable per institutional standards, patient may be enrolled; CMV PCR will be tested within two weeks prior to starting study drug
Positive test for HIV
HIV positive patients.
Subject is known to be HIV positive.
HIV positive
Known to be HIV-positive
Patients known to be HIV positive.
HIV positive
HIV positive
DONOR: HIV-positive
HIV-positive tetralogy of fallot (TET) patients are ineligible
Patients known to be HIV positive, hepatitis B positive, or hepatitis C positive.
HIV positive
nEGFR positive
Known positive for HIV
Known to be HIV-positive
DONOR: HIV positive
HIV-positive
Subjects who are known to be HIV positive
HIV positive.
Those who are HIV-positive will be excluded from the study
Known HIV positive patients
Known to be HIV-positive
Known HIV-positive
Patients who are HIV positive
Patients who are known to be HIV-positive.
Patients known to be HIV positive, hepatitis B positive, or hepatitis C positive.
Patients known to be HIV positive are ineligible.
HIV positive
Known HIV positive or on active anti-retroviral therapy
History of HIV positive
Patients known to be HIV positive, hepatitis B positive, or hepatitis C positive.
DONOR: HIV positive
DONOR: HIV-positive
Known history of immunodeficiency disorder other than HIV-positive status
DONOR: Individuals who are HIV-positive
Donors: HIV positive
HIV positive test within 8 weeks of screening
HIV positive patients
Known history of HIV positive status
HIV-positive subjects:
Patients who are HIV positive with an active AIDS-related illness are excluded; patients who are HIV positive but on stable therapy are not excluded.
HER2-positive disease
HER2 Positive
HIV positive patients receiving antivirals.
Patients with HER2 positive disease.
Known to be HIV positive. HIV testing is not required for those patients who are not known to be positive.
HIV-positive.
HIV-positive patients receiving anti-retroviral therapy are excluded from this study; HIV positive patients not receiving antiretroviral therapy are excluded
Known HIV positive.
Tested positive for HIV or hepatitis.
Known HIV positive.
Phase I: patient must not be known to be HIV-positive on combination antiretrovirals
Known HIV positive status
Subject has tested positive for HIV.
Known HIV-positive
Known HIV positive
Known HIV positive.
Known HIV-positive patients are excluded from the study
Known positive status for HIV
HIV Positive* * Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests available within 12 months before screening or at screening
Because of the concerns of potentially harmful interactions of TPI 287and other medications taken by patients who are HIV positive or have AIDS related diseases, patients who are HIV positive are not be eligible for entry into this study. Only patients with suspected HIV will be tested and if positive, will be ineligible.
Positive for HIV infection
Positive HIV test at screening
Known HIV positive and positive screening pregnancy test or is breast-feeding.
HIV-positive patients are ineligible
Patients known to be HIV positive
Is the subject HIV positive?
HIV-positive patients
Positive for human immunodefinciency (HIV) infection
Positive test for HIV antibodies
Known positive test for HIV
Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive Western Blot, or any other federally approved licensed HIV test; a positive HIV viral load prior to study entry will also be permitted
HIV positive
The patient is known to be HIV-positive.
HIV positive
The patient is known to be HIV-positive.
Standard blood tests that are positive for HIV infection
Known HIV positive.
Known HIV positive patients.
Subject is HIV positive
DONOR: HIV positive
Positive HIV test
Donors who are HIV positive (Patients who are HIV positive - if autologous product)
HIV positive
Patients must not have a history of chronic or active hepatitis B or C infection; patients must have negative hepatitis B and C serologies performed within 28 days prior to registration
Positive for Hepatitis C or Chronic Hepatitis C.
Participants with active chronic or acute hepatitis C or B infection
Active or chronic hepatitis B or hepatitis C.
Participants with known active or chronic infection with hepatitis B or C.
Participants with known acute or chronic hepatitis B or hepatitis C
Positive for Hepatitis C or chronic Hepatitis C
Chronic active Hepatitis B or C.
History of chronic hepatitis B or C
Has evidence of acute or chronic hepatitis B or hepatitis C
Subject has a diagnosis of chronic active hepatitis B or C.
Chronic, active, or acute viral hepatitis A, B, or C infection, or hepatitis B or C carrier
Active ongoing infection requiring therapy; patients with known chronic hepatitis C infection will be allowed if antiviral therapy is not in use; patients with evidence of chronic hepatitis B infection as evidenced by hepatitis B surface antigen positivity and/or evidence of hepatitis B circulating deoxyribonucleic acid (DNA) are required to receive viral prophylaxis while on treatment with entecavir or tenofavir per institutional guidelines; hepatitis viral load studies will be followed as described in protocol
Subject has active infectious hepatitis, type A, B, or C, or chronic carriers of hepatitis C.
History of hepatitis B or C or chronic hepatitis
Known history of chronic hepatitis B or C
Positive test results for chronic hepatitis B and hepatitis C infection
Active tuberculosis or hepatitis, or history of hepatitis B or C, or chronic hepatitis
Known or chronic hepatitis C and/or B infection
Chronic infection with hepatitis B or hepatitis C virus
Active or chronic hepatitis B infection
History of chronic hepatitis B or C
Chronic hepatitis infection, including B and C
Known active or chronic hepatitis B or C infection
Patients with history of active hepatitis B or C infection or chronic hepatitis with Child Pugh B or C hepatic dysfunction
Presence of any other active or suspected acute or chronic uncontrolled infection or known symptomatic active hepatitis B or C
Acute or chronic hepatitis B or C infection
History of chronic hepatitis B or C
History of chronic or active hepatitis
Chronic hepatitis B or hepatitis C infection
History of chronic or active hepatitis
History of chronic or active hepatitis
Acute or chronic hepatitis B or hepatitis C.
Prior, current, or chronic hepatitis B or hepatitis C infection
Patients with non-hepatocellular carcinoma must not have acute or chronic hepatitis B or hepatitis C infection
Subjects with a history of chronic or acute hepatitis C or B infection.
History of chronic hepatitis B or C infection
Patients with known acute or chronic hepatitis B or hepatitis C infection are ineligible
History of chronic hepatitis B or C
History of chronic hepatitis B or C
Chronic hepatitis C based on the judgment of the investigator
Chronic hepatitis infection, including B and C
Chronic hepatitis infection, including B and C
Patients who have chronic hepatitis B or hepatitis C
Known history of HIV seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment
Active or chronic infection of hepatitis B virus or hepatitis C
History of chronic hepatitis B infection or positive test results for active or chronic hepatitis B or hepatitis C
No active or chronic infection with hepatitis C
Has known history of Chronic Hepatitis B or C
Diagnosis of infection with HIV or chronic infection with hepatitis B or C
Known disease or history of active or chronic hepatitis C and/or B infection
Chronic active or acute viral hepatitis A, B, or C infection, or a hepatitis B or C carrier
Known acute or chronic hepatitis B or hepatitis C infection
No history of chronic hepatitis B or C
Acute or chronic active hepatitis B or C infection, or other serious chronic infection requiring ongoing treatment
Active or chronic hepatitis C and/or B infection
No active or chronic hepatitis C and/or B infection
Known history of chronic hepatitis B or C
Chronic active or acute viral hepatitis A, B, or C infection, or hepatitis B or C carrier
History of HIV infection or chronic hepatitis B or C
COHORT B: No active or chronic infection with HIV, hepatitis B or hepatitis C (negative screening tests required)
Prior, current, or chronic hepatitis B or hepatitis C infection
No history of chronic hepatitis B or or untreated hepatitis C.
Patients with a diagnosis of chronic hepatitis B are ineligible
Chronic active hepatitis B or C.
Active hepatitis B or hepatitis C, or laboratory evidence for a chronic infection.
Known history of chronic hepatitis B or C
Subject has a chronic or acute hepatitis C infection
Subject has a chronic or acute hepatitis B infection
Patients with acute or chronic hepatitis
History of HIV infection or active hepatitis B (chronic or acute) or hepatitis C infection
Known history of active or chronic hepatitis C and/or B infection
Prior, current, or chronic hepatitis B or hepatitis C infection
Chronic active or acute viral hepatitis A, B, or C infection or hepatitis B or C carrier
Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C)
Known acute or chronic hepatitis B or C
Positive test results for chronic hepatitis BsAg infection.
Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C), or hepatitis B or C carrier
Known active or chronic hepatitis B or hepatitis C infection
Chronic active hepatitis B or C infection
Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C), or hepatitis B or C carrier
Chronic hepatitis B or C infection.
Prior, current or chronic hepatitis B or hepatitis C infection
Chronic hepatitis B or C infection
History of chronic active hepatitis
Active/chronic hepatitis B or C
Known acute or chronic hepatitis B or hepatitis C infection as determined by serologic tests
Known acute or chronic hepatitis B or hepatitis C infection as determined by serologic tests
Chronic, active, or acute viral hepatitis A, B, or C infection, or a hepatitis B or C carrier
Active chronic hepatitis C and/or B infection
Known active or chronic hepatitis B or hepatitis C infection
Absence of known HIV infection, chronic hepatitis B, or hepatitis C infection; absence of any other serious medical condition which could interfere with oral medication intake
Opportunistic infection within the last 3 months
Concurrent opportunistic infections
Concurrent opportunistic infections
Concurrent opportunistic infections
Concurrent opportunistic infections
Concurrent opportunistic infections
Concurrent opportunistic infections
Concurrent opportunistic infections
Concurrent opportunistic infections
Concurrent opportunistic infections
Concurrent opportunistic infections
Concurrent opportunistic infections
Concurrent opportunistic infections
Concurrent opportunistic infections
Concurrent opportunistic infections
Active opportunistic infection or treatment for opportunistic infection within four weeks of first day of study drug dosing
No previous evidence of opportunistic infection
Concurrent opportunistic infections
Concurrent opportunistic infections
Concurrent opportunistic infections
Concurrent opportunistic infections
Uncontrolled opportunistic infection or treatment for opportunistic infection within 4 weeks of first day of study drug dosing
Concurrent opportunistic infections
Concurrent opportunistic infections
Active infections, including opportunistic infections
Concurrent opportunistic infections
Opportunistic infections
Concurrent opportunistic infections
Concurrent opportunistic infections
Patients with opportunistic viral infections other than CMV
Patients diagnosed with hepatitis C who are hepatitis C antibody positive, whether hepatitis C RNA level is measurable or not, must have no evidence of cirrhosis and have liver function tests
Positive screen for hepatitis B or C
Patients known to be human immunodeficiency virus (HIV) positive may be enrolled if baseline cluster of differentiation (CD)4 count is > 500 cells/mm^3 AND not taking anti-retroviral therapy; patients with known hepatitis are not eligible unless there is a known negative hepatitis panel; (exception: previous history of hepatitis A infection that is not currently active is allowed); patients must not have any known uncontrolled underlying pulmonary disease
Active hepatitis B or hepatitis C with abnormal liver function tests
Patients with known hepatitis B or hepatitis C are not eligible, regardless of concomitant antiretroviral therapy or current viral load
Recent history of hepatitis infection or if the treating physician determined that the patient would be at significant risk of reactivation of hepatitis
Must have Child-Pugh A only. Participants may have any viral status (hepatitis B, hepatitis C, or none).
Patients with clinically active hepatitis A, B, or C infections are not eligible\r\n* Note: patients with a history of hepatitis may be eligible if they have a normal titer; such cases should be approved by the study principal investigator (PI)
Patients with a known history of infection with hepatitis B or hepatitis C virus (active, previously treated, or both) will not be eligible due to the increased risk of hepatotoxicity and viral reactivation associated with systemic chemotherapy
Subject with seropositivity for hepatitis B or hepatitis C must be cleared by hepatology service prior to participating in treatment protocol
Patients with known hepatitis B or C; screening for hepatitis B and/or C is not required for eligibility for this study
SAFETY RUN-IN: Patients known to be carriers of hepatitis virus B and C
Prior to start of everolimus, the following three categories of patients should be tested for hepatitis B viral load and serologic markers, that is, HBV-DNA, HBsAg, hepatitis B surface (HBs) antibody (Ab), and hepatitis B core (HBc) Ab\r\n* All patients who currently live in (or have lived in) Asia, Africa, Central and South America, Eastern Europe, Spain, Portugal and Greece\r\n* Patients with any of the following risk factors:\r\n** Known or suspected past hepatitis B infection,\r\n** Blood transfusion(s) prior to 1990,\r\n** Current or prior intravenous (IV) drug users,\r\n** Current or prior dialysis,\r\n** Household contact with hepatitis B infected patient(s),\r\n** Current or prior high-risk sexual activity,\r\n** Body piercing or tattoos,\r\n** Mother known to have hepatitis B\r\n** History suggestive of hepatitis B infection, e.g., dark urine, jaundice, right upper quadrant pain\r\n** Additional patients at the discretion of the investigator
Patients with any of the following risk factors for hepatitis C should be tested using quantitative RNA-polymerase chain reaction (PCR):\r\n* Known or suspected past hepatitis C infection (including patients with past interferon ‘curative’ treatment),\r\n* Blood transfusions prior to 1990,\r\n* Current or prior IV drug users,\r\n* Current or prior dialysis,\r\n* Household contact of hepatitis C infected patient(s),\r\n* Current or prior high-risk sexual activity,\r\n* Body piercing or tattoos\r\n* At the discretion of the investigator, additional patients may also be tested for hepatitis C
Hepatitis B or C
History of hepatitis B
Has a known history of Hepatitis B or Hepatitis C.
Hepatitis B or C
Patients with history of hepatitis B and hepatitis C will be eligible but patients with hepatitis B must be started on antiviral therapy prior to beginning study therapy
Positive for Hepatitis B
COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Patients who have known active hepatitis B, or hepatitis C infections
Patients with known active human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection; patients with a history of hepatitis B or hepatitis C, who are deemed cured and no longer require treatment may be allowed to enroll after consultation with the respective specialist and the study PI
Key Inclusion Criteria:\n\n        Up to 5 prior regimens for MCL. Prior therapy must have included:\n\n          -  Anthracycline or bendamustine-containing chemotherapy and\n\n          -  Anti-CD20 monoclonal antibody therapy and\n\n          -  Ibrutinib or acalabrutinib\n\n        At least 1 measurable lesion\n\n        Platelet count ? 75,000/uL\n\n        Creatinine clearance (as estimated by Cockcroft Gault) > 60 mL/min\n\n        Cardiac ejection fraction ? 50%, no evidence of pericardial effusion as determined by an\n        ECHO, and no clinically significant ECG findings\n\n        Baseline oxygen saturation >92% on room air.\n\n        Key Exclusion Criteria:\n\n          -  Known history of infection with HIV or hepatitis B (HBsAG positive) or hepatitis C\n             virus (anti-HCV positive). A history of hepatitis B or hepatitis C is permitted if the\n             viral load is undetectable per standard serological and genetic testing\n\n          -  History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia,\n             cerebellar disease, cerebral edema, posterior reversible encephalopathy syndrome, or\n             any autoimmune disease with CNS involvement\n\n          -  Presence of fungal, bacterial, viral, or other infection that is uncontrolled or\n             requiring IV antimicrobials for management.
Patients must have no evidence of significant hematologic, renal, or hepatic dysfunction; patients with underlying hepatocellular disease should be given careful risk/benefit consideration prior to enrollment; patients with a history of any chronic hepatitis as evidenced by the following are ineligible:\r\n* Positive test for hepatitis B surface antigen (HBsAg)\r\n* Positive test for qualitative hepatitis C viral load (by PCR) (Note: subjects with positive hepatitis C antibody and negative quantitative hepatitis C by PCR are eligible; history of resolved hepatitis A virus infection is not an exclusion criterion)\r\n* History of alcoholic or non-alcoholic steatohepatitis (NASH), auto-immune hepatitis, or previous grade 3-4 drug-related hepatitis, or any form of chronic liver disease
Patients with treated hepatitis virus infections (hepatitis B or hepatitis C) are eligible if they have been definitively treated for 6 months, have no detectable viral load on quantitative PCR, and liver function tests (LFTs) meet eligibility requirements
Known positivity for hepatitis B or C
Patients who are carriers of hepatitis virus B and C; hepatitis B and C testing must be performed to confirm status prior to enrollment
Patients who are carriers of hepatitis B will be included in this study
Known hepatitis B or hepatitis C with abnormal liver function tests
Patients with a known history of human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or tuberculosis infection; patients with a history of cleared hepatitis C (undetectable viral loads) are allowed
Patients with a known history of hepatitis B or hepatitis C
Negative for hepatitis B surface antigen; positive hepatitis B tests can be further evaluated by confirmatory tests; and if confirmatory tests are negative, the patient can be enrolled; patients with a known history of hepatitis B are not eligible
All participants will be required to be screened for hepatitis C; if hepatitis C antibody positive, with or without a positive hepatitis C RNA level, participants will be permitted to enroll in the study provided liver function tests meet criteria listed, and have no evidence of cirrhosis; participants diagnosed with hepatitis C less than 6 months from trial enrollment will be considered to have acute hepatitis C, and will be excluded from study UNLESS hepatitis C viral load is undetectable
On treatment for hepatitis B or hepatitis C or history of tuberculosis (TB)
Known hepatitis B or hepatitis C infection; EXCEPTION: if viral load < 800,000 IU/L
Subjects must not have a history of any positive test for hepatitis B or hepatitis C indicating active disease or previous exposure
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient’s participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator; this includes known active tuberculosis; grade 3 active infection; history of allogeneic bone marrow transplant or solid organ transplant; known history of human immunodeficiency virus (HIV); known active hepatitis B (eg, hepatitis [Hep] B deoxyribonucleic acid [DNA] positive in prior 3 months) or known active hepatitis C (eg, hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected in prior 3 months)
Hepatitis C on protease therapy
Has known hepatitis B or hepatitis C
Has known active hepatitis B or C; active hepatitis B is defined as a known positive hepatitis B surface antigen (HBsAg) result; active hepatitis C is defined by a known positive hepatitis (Hep) C antibody (Ab) result and known quantitative hepatitis C virus (HCV) ribonucleic acid (RNA) results greater than the lower limits of detection of the assay
Patients positive for hepatitis C are permitted if controlled with medication, in the opinion of the investigator
Patients who are hepatitis B or C positive
Patients with a known history of hepatitis B or hepatitis C are not eligible
Seronegative for hepatitis B antigen, positive hepatitis B tests can be further evaluated by confirmatory tests, and if confirmatory tests are negative, the patient can be enrolled; patients with a known history of hepatitis B are not eligible
Evidence of active infection by hepatitis B and/or C; for patients with hepatitis B treated with anti-virals to undetectable viral load, and for patients with hepatitis C with undetectable ribonucleic acid (RNA) levels and no evidence of liver damage, enrollment may be considered and should discuss first with study’s principal investigator
Patients with a known history of hepatitis B or C
Patients with active hepatitis B or C infection (not including patients with prior hepatitis B vaccination); these patients should be cleared by gastrointestinal (GI) consultation for hepatitis B and infectious disease consult for hepatitis C
Patients with a positive history of hepatitis B or hepatitis C
Active hepatitis B or hepatitis C with abnormal liver function tests; HIV positive patients receiving antivirals.
Baseline hepatitis titers without evidence of acute/active hepatitis
Patients with known hepatitis or unstable liver disease, and/or positive serologies for Hepatitis B or C and HIV.
Known history of hepatitis B or C as these patients may be at risk of disease reactivation when treated with the chemotherapy and/or the investigational agent
Known Hepatitis B Ag positive, Hepatitis C positive patients
Patients known to be have active hepatitis B or C; (hepatitis B positive patients are allowed if they are on appropriate antiviral agents such as lamivudine)
Has autoimmune hepatitis
Patients with clinical symptoms of hepatitis B and/or hepatitis C will be tested, if clinically indicated per medical records review; if no indications exist in clinical evaluation or laboratory values that are consistent with hepatitis, patients will not be routinely tested for hepatitis B virus (HBV)/hepatitis C virus (HCV); positive results will be an exclusion criteria
Known history of or positive test for hepatitis B or hepatitis C infection.
Hepatitis B and C negative
Known hepatitis B or C
Seropositive for any of the following: HIV ab, hepatitis B sAg, hepatitis (hep) C immunoglobulin (Ig)G Ab positive, without definitive therapy for hepatitis C; or hepatitis C PCR positivity; or hepatitis C IgM positivity
Patients who have any known history of liver disease, autoimmune hepatitis, sclerosing cholangitis or are found to be carriers (active disease or not) of hepatitis B and hepatitis C
Active viral hepatitis or autoimmune hepatitis; the work-up to confirm active hepatitis or autoimmune hepatitis will only be done if clinical suspicion based on investigator discretion
Seronegative for hepatitis B antigen, positive hepatitis B tests can be further evaluated by confirmatory tests, and if confirmatory tests are negative, the patient can be enrolled
Active hepatitis B or hepatitis C with abnormal liver function tests
Patients with known hepatitis B or hepatitis C infection must have viral load < 800,000 IU/L within 28 days prior to registration
Patients with hepatitis C antibody will be eligible provided that they do not have elevated liver transaminases or other evidence of active hepatitis
Patients with evidence of hepatitis B or hepatitis C PCR positivity
Patients with hepatitis B
Has known history of or is positive for Hepatitis B or Hepatitis C
History of hepatitis (B or C)
Active coinfection with both hepatitis B (i.e., HBVsAg and/or hepatitis B DNA) and hepatitis C (i.e., hepatitic C RNA)
Hepatitis B or C positive
Subject with a known history of active chronic HIV, hepatitis B or hepatitis C infections; negative hepatitis C viral load is allowed
Patients with known hepatitis B or hepatitis C infection may be eligible providing they have viral load < 800,000 IU/L within 28 days prior to registration
Negative screening tests for hepatitis B and hepatitis C; patients with positive results that do not indicate true active or chronic infection may enroll after discussion and consensus agreement by the treating physician and principal investigator
Patients with treated hepatitis virus infections (hepatitis B or hepatitis C) are eligible if they have been definitively treated for 6 months, have no detectable viral load on quantitative PCR, and liver function tests (LFTs) meet eligibility requirements
Patients with active hepatitis B or C. Screening for hepatitis B Prior to randomization/start of everolimus, the following three categories of patients should be tested for hepatitis B viral load and serologic markers, that is, HBsAg, HBcAb, HBsAb and quantitative hepatitis B DNA PCR (HBV-DNA): • All patients who currently live in (or have lived in) Asia, Africa, Central and South America, Eastern Europe, Spain, Portugal and Greece. [http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-trave l/hepatitis-b.htm]
mother known to have hepatitis B
Additional patients at the discretion of the investigator The management guidelines, in Section 6, are provided according to the results of the baseline assessment of viral load and serological markers for hepatitis B. Screening for hepatitis C Patients with any of the following risk factors for hepatitis C should be tested using quantitative RNA-PCR:
Known history of or is positive for Hepatitis B or Hepatitis C
Patients with history of untreated hepatitis B or who are known carriers of hepatitis B will be excluded from this trial; all subjects will be screened prior to study entry
A risk of reactivation of hepatitis B or C.
Have achieved a sustained virologic response for 12 weeks after cessation of hepatitis C antiviral treatment (in HIV-positive subjects with hepatitis C)
Seronegative for hepatitis B antigen, positive hepatitis B tests can be further evaluated by confirmatory tests (hepatitis B [Hep B] deoxyribonucleic acid [DNA] quantitative [Quant], hepatitis B virus [HBV] viral load), and if confirmatory tests are negative, the patient can be enrolled
Participant has known active Hepatitis B, Hepatitis C or tuberculosis. Active Hepatitis B is defined as a known positive HBsAg result. Active Hepatitis C is defined by a known positive Hepatitis C antibody result and known quantitative Hepatitis C virus (HCV) ribonucleic acid (RNA) results greater than the lower limits of detection of the assay.
Positive hepatitis B (hepatitis B surface antigen and antibody) and/or hepatitis C (hepatitis C antibody test) as indicated by serologies conducted =< 3 months prior to starting study if liver function tests are outside of the normal institutional range\r\n* NOTE: patients with hepatitis B or C serologies indicating active infection without known active disease must meet the eligibility requirements for ALT, AST, total bilirubin, INR, PTT, and alkaline phosphatase on at least two consecutive occasions, separated by at least 1 week
All patients must be willing to be tested for hepatitis screening; patients co-infected with hepatitis B virus and/or hepatitis C virus may be included in this study provided that their liver function tests remain within the limits listed above; patients must be followed by a hepatologist during the course of this study
Active hepatitis B or hepatitis C with abnormal liver function tests.
Hepatitis B or C
History of hepatitis B or C
Hepatitis B or C
All patients known to be positive for hepatitis B will be excluded from the study, and those at high risk for hepatitis B infection will be screened
Subjects with acute hepatitis
History of interstitial lung disease, prior malignancy, active autoimmune disease, positive test for hepatitis B or hepatitis C virus
Active hepatitis B as defined by hepatitis B surface antigen positivity, unless able to start dual anti-hepatitis B (HepB) therapy, or already on dual anti-HepB therapy
Patients with a known history of liver disease, autoimmune hepatitis, sclerosing cholangitis, or hepatitis B or C are not eligible for participation
Patients with known hepatitis or unstable liver disease, and/or positive serologies for Hepatitis B or C and HIV.
Known positive patients for infectious hepatitis, type A, B, C
Subjects with confirmed Hepatitis A, B or C
Active hepatitis B or hepatitis C with abnormal liver function tests.
Has a known history of Hepatitis B
Seropositivity or DNA/RNA positivity for hepatitis B or C, with the exception of patients who have received prior Hepatitis B vaccination and are Anti-HBs positive only
Patients who have not been tested within 3 months prior to starting adjuvant therapy must be tested for hepatitis B and hepatitis C serologies during study screening\r\n* Patients with positive hepatitis B or C serologies without known active disease must meet the eligibility requirements for ALT, AST, total bilirubin, international normalized ratio (INR), activated partial thromboplastin time (aPTT), and alkaline phosphatase on at least two consecutive occasions, separated by at least 1 week, within the 30 day screening period
Hepatitis B with positive viral load prior to transplant conditioning or hepatitis C virus
History of hepatitis B or C infection (subjects with evidence of cleared hepatitis B are permitted).
Patients must have negative hepatitis C virus (HCV) serology; all patients must be screened for hepatitis B infection before starting treatment; those patients who test positive for hepatitis B should be closely monitored for evidence of active hepatitis B virus (HBV) infection and hepatitis during and for several months after rituximab treatment; PCNSL patients with a history of hepatitis B infection should be treated with entecavir or lamivudine (physician discretion for choice of drug) as antiviral prophylaxis to prevent hepatitis B reactivation
Presence of known hepatitis B or hepatitis C infection, regardless of control on antiviral therapy
Current or known history of hepatitis
Has known history of or is positive for hepatitis B or hepatitis C
HIV positivity (NOTE: patients positive for hepatitis B or hepatitis C are not excluded, and may be evaluated on a case-by-case basis)
Has a known history of active hepatitis B or C. Healthy carriers of hepatitis B are not allowed on this study
Patients with hepatitis B and C will be excluded
Known history of hepatitis C and recovery status has not been determined at time of screening
Patients with hepatitis
Known to be positive for hepatitis B. Known to have active hepatitis C infection or on antiviral therapy for hepatitis C within the last 6 months.
Patients known to be seropositive for hepatitis C hepatitis B
History of any hepatitis (A,B or C)
Patients with known hepatitis B or hepatitis C infection may be eligible providing they have viral load < 800,000 IU/mL within 28 days prior to registration
History of any hepatitis (A, B or C)
History of grade 3-4 drug-related hepatitis
Known positive for Human Immunovirus (HIV) or infectious Hepatitis type C or active infectious Hepatitis type B.
Circulating hepatitis C virus on qPCR
Hepatitis B or C.
Positive for hepatitis BsAg or HIV Ab or hepatitis C
A Hepatitis B/C blood test must be done at screening for all patients; patients who test positive for Hepatitis C antibodies and the Hepatitis B antigen are ineligible
Patients with known history of autoimmune hepatitis, hepatitis C or those with hemoglobinopathies (e.g., thalassemia major, sickle cell anemia)
History of hepatitis A, B and C
Known positive for infectious hepatitis type C or active infectious hepatitis type B
Known hepatitis B or C
Patient is known to be hepatitis B or hepatitis C-positive (these tests are not required)
Known history of infection with HIV, hepatitis B (HBsAg positive), or hepatitis C (anti-HCV positive). A history of treated hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative PCR and/or nucleic acid testing.
History of any hepatitis
Patients with hepatitis B and hepatitis C must be under the care of viral hepatitis expert consultant; patients with hepatitis B are required to be treated with anti-hepatitis B virus (HBV) treatment (e.g., entecavir); patients with hepatitis C need to have received prior and/or ongoing hepatitis C treatment
Known active viral or nonviral hepatitis or cirrhosis
Active or chronic viral hepatitis B or C infection
Active hepatitis B viral infection (defined as HBsAg+).
Participants with hepatitis B should be on appropriate anti-viral therapy at the time of the transplant, and their viral load should be negative; timeline: within 3 weeks prior to enrollment
Patients with cirrhosis, or active viral or nonviral hepatitis
Patients with known (testing is not part of the protocol) active hepatic disease (i.e., hepatitis B or C) due to risk of drug interactions with anti-viral therapy
Active hepatitis viral infections
HIV or hepatitis C - presence of viral load
Patients with cirrhosis, or active viral or nonviral hepatitis
Patients with active viral hepatitis.
Active or symptomatic viral hepatitis or chronic liver disease
Active or chronic viral hepatitis B or C infection Exclusions Related to Ocular Disease
Known active hepatitis, type B or C; patients on suppressive therapy with a negative viral load and no evidence of hepatic damage are eligible
Active or symptomatic viral hepatitis or chronic liver disease
Active or symptomatic viral hepatitis or chronic liver disease.
Active or symptomatic viral hepatitis or chronic liver disease.
Subjects with known HIV or active viral hepatitis
Known active viral or nonviral hepatitis or cirrhosis
Active liver disease, including viral or other hepatitis, or cirrhosis
Active hepatitis B. Patients with chronic hepatitis B who are on appropriate viral suppressive therapy may be allowed after discussion with the principal investigator (PI).
Active viral hepatitis A, B, or C or preexisting or acute liver disease;
Chronic active or active viral hepatitis A, B, or C infection
Known active viral hepatitis, HIV or chronic liver disease.
Active or symptomatic viral hepatitis or chronic liver disease
Known active or symptomatic viral hepatitis or chronic liver disease
Active hepatitis, including but not limited to viral and drug-induced
Active or symptomatic viral hepatitis or chronic liver disease
Active or symptomatic viral hepatitis or chronic liver disease
Known active viral or other chronic types hepatitides (hepatitis B, C) or cirrhosis
Known active viral or nonviral hepatitis or cirrhosis
Patients with hepatitis B and/or hepatitis C infection are excluded if they are on any of the following viral suppressive agents: boceprevir (Victrelis), ribavirin (Rebetol, Ribatab, Ribasphere), telaprevir (Incivek)\r\n* Note: patients with active hepatitis B infection must be on treatment with viral suppressive therapies; these agents may include the following: adefovir (Hepsera), entecavir (Baraclude), lamivudine (Epivir-HBV), telbivudine (Tyzeka), and/or tenofovir (Viread)
Active liver disease (i.e., cirrhosis, viral or autoimmune hepatitis, etc.)
Patients with cirrhosis, or active viral or non-viral hepatitis
Patients with a history of hepatitis C, but have a negative viral load, are eligible
Patients with PRIMARY HEPATIC CANCER must have an undetectable viral load for Hepatitis B and C.
Known acute viral hepatitis
Active viral hepatitis.
Active symptomatic viral hepatitis or chronic liver disease
DONOR: Evidence of active infection or viral hepatitis
DONOR: Evidence of active infection or viral hepatitis
Known active viral or nonviral hepatitis or cirrhosis
Active viral hepatitis, active human immunodeficiency virus (HIV) or chronic liver disease.
Known active viral or nonviral hepatitis or cirrhosis
Known active or chronic viral hepatitis or history of any type of hepatitis within the last 6 months
Any chronic or concurrent acute liver disease, including viral hepatitis
Active/uncontrolled viral hepatitis
History of, or presently active or chronic viral infections (i.e. zoster or hepatitis)
Active viral hepatitis
Active or symptomatic viral hepatitis or chronic liver disease
A diagnosis of active hepatitis B or C as defined by detectable viral load assays in the blood
Known active or chronic viral hepatitis or history of any type of hepatitis within the last 6 months.
Active or symptomatic viral hepatitis or chronic liver disease
Active or symptomatic viral hepatitis or chronic liver disease
Known active viral infection\r\n* Note: viral hepatitis testing is required at screening for all patients
Active or symptomatic viral hepatitis
Severe active viral infection, especially hepatitis B.
Active liver disease, including viral or other hepatitis, or cirrhosis
Known acute viral hepatitis
Patients with active viral hepatitis
Active or chronic viral hepatitis or history of any type of hepatitis within the last 6 months
Active viral hepatitis
Active or symptomatic viral hepatitis or chronic liver disease
Active or symptomatic viral hepatitis or chronic liver disease
Active or symptomatic viral hepatitis or chronic liver disease, including Child-Pugh class B and C liver disease
Active or symptomatic viral hepatitis or chronic liver disease
Active or symptomatic viral hepatitis or chronic liver disease
Active hepatitis B or C viral infection
Participants who are known to have active hepatitis A, B, or C viral infection may not participate in this study; active disease is defined as participants with a known viral hepatitis whose liver function tests are elevated beyond the criteria indicated
Known or active HIV, viral hepatitis B or C
DONOR: Evidence of active infection or viral hepatitis
Active or uncontrolled clinically serious infection. (Participants with chronic viral hepatitis are eligible.)
Active or symptomatic viral hepatitis or chronic liver disease
Subject has known active liver disease, including viral hepatitis or cirrhosis.
Active or symptomatic viral hepatitis or chronic liver disease
Known active viral or nonviral hepatitis
Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection, patients are excluded
Any positive test result for hepatitis B virus or hepatitis C virus indicating presence of virus
Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
Participants with known positive test for hepatitis B or C indicating acute or chronic infection
Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection, and/or detectable virus.
Any positive test result for hepatitis B or C indicating acute or chronic infection and/or detectable virus
Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection.
Any positive test result for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
Any positive test result for hepatitis B or C virus indicating acute or chronic infection.
Any known positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection is not permitted
Any positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection
Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
Any positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection
Patients who have any positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection are excluded
Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
Known history of a positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
Any known positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection is not permitted
Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
Any positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection.
Any positive test result for hepatitis B or C indicating acute or chronic infection
Any known positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection is not permitted
Any positive test result for hepatitis B or C virus indicating acute or chronic infection
Any known positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
Any positive test result for hepatitis B virus or hepatitis C virus indicating acute or chronic infection.
Any positive test for hepatitis B virus or hepatitis C virus indicating acute infection
Any positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) indicating acute or chronic infection
Any positive tests for Hepatitis B or Hepatitis C virus indicating acute or chronic infection